Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

bavituximab in combination with chemotherapy. The first bavituximab breast cancer trial is now underway and the two other trials are expected to begin soon. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. (Nasdaq: ... hold a conference call and live audio webcast on ... discuss its third quarter 2014 financial results. ... by dialing (888) 347-1165 for domestic callers or (412) ... webcast live under the investor relations section of the ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... Strategic Marketing ... Expertise, ... today announced that it has appointed David P.,Pauluzzi to its Board ... Partners, a Chicago-based private equity firm,specializing in the healthcare sector., ...
... DRRX ) announced today financial results for the ... were $6.6 million for the,three months ended December 31, ... 2006. Net loss for the three months ended December ... of $9.8 million for the same period in,2006., ...
... 5 Physicians Reference,Laboratory ("PRL") announced today that it ... date. Under the marketed,name COMPLeTe Care HPV, the test ... risk types of HPV which can lead to,cervical cancer., ... form of female,cancer with an incidence of over 500,000 ...
Cached Biology Technology:Transgenomic Appoints David Pauluzzi to Board of Directors 2Transgenomic Appoints David Pauluzzi to Board of Directors 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Physicians Reference Laboratory Announces New Diagnostic for Women's Health 2
(Date:10/31/2014)... and his team have been studying the behavior ... Austrian Alps for years. They observed that ravens ... grooming and playing. However, they also observed that ... third individual. Although in about 50 % of ... up the two affiliating ravens, intervening can be ...
(Date:10/30/2014)... German . ... humans to behave socially? This is one of the ... Previous studies assumed that it is almost impossible to ... Max Planck Institute for Evolutionary Biology have now demonstrated ... the cooperative behaviour of others. However, the possibilities available ...
(Date:10/30/2014)... , Oct. 29, 2014  Securus ... criminal justice technology solutions for public safety, ... it has deployed exciting enhancements to its ... analytics to provide actionable intelligence and focused ... continues to drive technological innovation through identifying ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2
... Could our mother,s diet at the time we are conceived ... is at the heart of a new study based on ... We inherit our DNA the genetic blueprint that ... DNA from our mothers and 50% from our fathers. Apart ...
... responsible for some of the worst air quality conditions worldwide ... changes in land use and population density, according to a ... Field of the University of Toronto. "During the late ... fire-prone during drought years, marking the period when one of ...
... BEVERLY, Mass., Feb. 17 LocatePLUS Holdings ... business-to-government provider of investigative, identity validation, and ... 26, 2009 election of an entirely independent ... independent Board through the consent of a ...
Cached Biology News:'Experiment of nature' examines how mother's diet may impact on child's health 2'Experiment of nature' examines how mother's diet may impact on child's health 3Atmospheric scientists trace the human role in Indonesian forest fires 2LocatePLUS Announces Election of Independent Board 2LocatePLUS Announces Election of Independent Board 3LocatePLUS Announces Election of Independent Board 4
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... cassette is designed to allow ... The prokaryotic promoter gb2 driving the ... slightly modified version of the Em7 ... than the generally used Tn5 promoter. ...
... AMPure is a magnetic bead-based ... no sample transfer, centrifugation or ... small and large PCR extension ... microplates. Agencourt AMPure can easily ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: